4 月速览
3 月速览
1 月速览
1 月速览
12 月速览
11 月速览
10 月速览
9 月速览
8 月速览
7 月速览
6 月速览
5 月速览
4 月速览
3 月速览
2 月速览
1 月速览
12 月速览
12 月速览
11 月速览
10 月速览
9 月速览
8 月速览
7 月速览
11 月速览
10 月速览
9 月速览
8 月速览
7 月速览
6 月速览
5 月速览
4 月速览
3 月速览
2 月速览
1 月速览
12 月速览
11 月速览
10 月速览
9 月速览
8 月速览
7 月速览
6 月速览
5 月速览
4 月速览
3 月速览
2 月速览
1 月速览
12 月速览
11 月速览
10 月速览
9 月速览
8 月速览
7 月速览 (上)
7 月速览 (下)
6 月速览 (上)
6 月速览 (中)
6 月速览 (下)
5 月速览 (上)
5 月速览 (中)
5 月速览 (下)

Neuro Oncology

2025
2024
2023
2022
2021
2020

本篇文献由机器智能翻译

【Online】2024年10月速览
  • EVA1-Antibody Drug Conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells

    EVA1-Antibody药物偶联物是消除胶质母细胞瘤起始细胞的新治疗策略

    The discovery of glioblastoma (GBM)-initiating cells (GICs) has impacted GBM research. These cells are not only tumorigenic, but also exhibit resistance to radiotherapy and chemotherapy. Therefore, it is crucial to characterize GICs thoroughly and identify new therapeutic targets. In a previous study, we successfully identified Epithelial V-like antigen 1 (EVA1) as a novel functional factor specific to GICs. Our data indicate that B2E5-ADC is a new and promising therapeutic strategy for GBM.

    胶质母细胞瘤 (GBM) 起始细胞 (gic) 的发现影响了GBM的研究。这些细胞不仅具有致瘤性,而且对放疗和化疗表现出抗性。因此,彻底表征gic并确定新的治疗靶标至关重要。在先前的研究中,我们成功地将上皮V样抗原1 (EVA1) 鉴定为GICs特异性的新功能因子。我们的数据表明,B2E5-ADC是GBM的一种新的有希望的治疗策略。

    REF: Hou J, Uejima T, Tanaka M, et al. EVA1-Antibody Drug Conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells. Neuro Oncol. Published online October 29, 2024. doi:10.1093/neuonc/noae226 PMID: 39470407

  • Sleep disorders associated with cranial radiation – a systematic review

    与颅辐射相关的睡眠障碍-系统综述

    Radiation is standard-of-care treatment for primary brain tumors but may have profound effects on sleep that have not yet been fully characterized. This systematic review aims to further our understanding of radiation therapy on risk of development of sleep disorders in patients with primary brain tumors (PBTs), as well as potential opportunities for prevention and treatment. This systematic review highlights the ongoing challenges with sleep symptoms/disorders related to cranial irradiation treatment in the primary brain tumor population. Further investigations on the interconnectedness of sleep disturbance constructs and possible pharmacotherapies to alleviate symptoms are warranted.

    辐射是原发性脑肿瘤的标准治疗,但可能对尚未完全表征的睡眠产生深远影响。本系统综述旨在进一步了解放射治疗对原发性脑肿瘤 (pbt) 患者睡眠障碍发展的风险以及预防和治疗的潜在机会。这项系统综述强调了与原发性脑肿瘤人群中与颅骨放射治疗相关的睡眠症状/障碍的持续挑战。有必要进一步研究睡眠障碍结构的相互联系以及减轻症状的可能药物疗法。

    REF: Pascoe M, Byrne E, King A, et al. Sleep disorders associated with cranial radiation - a systematic review. Neuro Oncol. Published online October 28, 2024. doi:10.1093/neuonc/noae174 PMID: 39468721

  • Imaging PD-L1 in the brain—Journey from the lab to the clinic

    大脑中的成像PD-L1-从实验室到诊所的旅程

    Immune checkpoint inhibitors (ICPIs) have proven to restore adaptive anti-tumor immunity in many cancers; however, no noteworthy therapeutic schedule has been established for patients with glioblastoma (GBM). High programmed death-ligand 1 (PD-L1) expression is associated with immunosuppressive and aggressive phenotypes in GBM. Presently, there is no standardized protocol for assessing PD-L1 expression levels to select patients and monitor their response to ICPI therapy. The aim of this study was to investigate the use of 89Zr-DFO-Atezolizumab to image the spatio-temporal distribution of PD-L1 in preclinical mouse models and in patients with newly diagnosed GBM treated with/without neoadjuvant Pembrolizumab. 89Zr-DFO-Atezolizumab can visualize distinct PD-L1 expression levels with high specificity in preclinical mouse models and in patients with GBM, whilst complementing ex vivo analysis.

    免疫检查点抑制剂 (icpi) 已被证明可以在许多癌症中恢复适应性抗肿瘤免疫; 然而,对于胶质母细胞瘤 (GBM) 患者,尚未建立值得注意的治疗方案。高程序性死亡配体1 (PD-L1) 表达与GBM的免疫抑制和侵袭性表型相关。目前,没有用于评估PD-L1表达水平以选择患者并监测其对ICPI治疗的反应的标准化方案。这项研究的目的是研究使用89Zr-DFO-Atezolizumab对临床前小鼠模型以及使用/不使用新辅助Pembrolizumab治疗的新诊断GBM患者的PD-L1时空分布进行成像。89Zr-DFO-Atezolizumab可以在临床前小鼠模型和GBM患者中以高特异性可视化不同的PD-L1表达水平,同时补充离体分析。

    REF: Dar D, Rodak M, Da Pieve C, et al. Imaging PD-L1 in the brain-Journey from the lab to the clinic. Neuro Oncol. Published online October 28, 2024. doi:10.1093/neuonc/noae190 PMID: 39470381

  • Prospective Longitudinal Analysis of Physiologic MRI-based Tumor Habitat Predicts Short-term Patient Outcomes in IDH-wildtype Glioblastoma

    基于生理性MRI的肿瘤栖息地的前瞻性纵向分析可预测IDH野生型胶质母细胞瘤的短期患者预后

    This study validates MRI-based tumor habitats in predicting time-to-progression (TTP), overall survival (OS), and progression site in isocitrate dehydrogenase (IDH)-wildtype glioblastoma patients. Multiparametric physiologic MRI-based spatiotemporal tumor habitats and habitat risk scores are useful biomarkers for early tumor progression and outcomes in IDH-wildtype glioblastoma patients

    这项研究验证了基于MRI的肿瘤栖息地在预测异柠檬酸脱氢酶 (IDH)-野生型胶质母细胞瘤患者的进展时间 (TTP),总生存期 (OS) 和进展部位方面的作用。基于多参数生理MRI的时空肿瘤栖息地和栖息地风险评分是IDH野生型胶质母细胞瘤患者早期肿瘤进展和预后的有用生物标志物

    REF: Moon HH, Park JE, Kim NY, et al. Prospective Longitudinal Analysis of Physiologic MRI-based Tumor Habitat Predicts Short-term Patient Outcomes in IDH-wildtype Glioblastoma. Neuro Oncol. Published online October 25, 2024. doi:10.1093/neuonc/noae227 PMID: 39450860

  • Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations

    恶性神经胶质瘤患者的嵌合抗原受体T细胞疗法-从神经免疫学到临床试验设计考虑

    Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in patients with malignant gliomas have shown some early promise in pediatric and adult patients. However, the long-term benefits and safety for patients remain to be established. The ultimate success of CAR T-cell therapy for malignant glioma will require the integration of an in-depth understanding of the immunology of the central nervous system (CNS) parenchyma with strategies to overcome the paucity and heterogeneous expression of glioma-specific antigens. We also need to address the cold (immunosuppressive) microenvironment, exhaustion of the CAR T-cells, as well as local and systemic immunosuppression. Here, we discuss the basics and scientific considerations for CAR T-cell therapies and highlight recent clinical trials. To help identify optimal CAR T-cell administration routes, we summarize our current understanding of CNS immunology and T-cell homing to the CNS. We also discuss challenges and opportunities related to clinical trial design and patient safety/monitoring. Finally, we provide our perspective on future prospects in CAR T-cell therapy for malignant gliomas by discussing combinations and novel engineering strategies to overcome immuno-regulatory mechanisms. We hope this review will serve as a basis for advancing the field in a multiple discipline-based and collaborative manner.

    在恶性神经胶质瘤患者中评估嵌合抗原受体 (CAR) T细胞疗法的临床试验已在儿科和成人患者中显示出一些早期前景。然而,对患者的长期益处和安全性仍有待确定。CAR T细胞治疗恶性神经胶质瘤的最终成功将需要对中枢神经系统 (CNS) 实质免疫学的深入理解与克服神经胶质瘤特异性抗原的缺乏和异质表达的策略相结合。我们还需要解决寒冷 (免疫抑制) 的微环境,CAR T细胞的耗尽以及局部和全身免疫抑制。在这里,我们讨论了CAR T细胞疗法的基础和科学考虑,并重点介绍了最近的临床试验。为了帮助确定最佳的car-t细胞给药途径,我们总结了我们目前对CNS免疫学和T细胞归巢到CNS的理解。我们还讨论了与临床试验设计和患者安全/监测相关的挑战和机遇。最后,我们通过讨论克服免疫调节机制的组合和新的工程策略,提供了我们对car-t细胞治疗恶性神经胶质瘤的未来前景的看法。我们希望这次审查将作为以多学科为基础和协作方式推进该领域的基础。

    REF: Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H. Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations. Neuro Oncol. Published online October 24, 2024. doi:10.1093/neuonc/noae203 PMID: 39450490

  • GDH1-catalytic glutaminolysis feedback activate EGFR/PI3K/AKT pathway and reprogram glioblastoma metabolism

    GDH1-catalytic谷氨酰胺分解反馈激活EGFR/PI3K/AKT通路并重新编程胶质母细胞瘤代谢

    Glutamine is an important nutriment for cancer cell growth that provides biological sources for nucleic acid and fatty acid synthesis, but the role of glutaminolysis in signal transduction and glioblastoma (GBM) progression remains little known. These findings suggest a novel function of glutaminolysis in regulation of signal transduction and metabolism reprograming, provide further evidence for unique role of glutaminolysis in GBM progression.

    谷氨酰胺是癌细胞生长的重要营养素,为核酸和脂肪酸合成提供生物来源,但谷氨酰胺分解在信号转导和胶质母细胞瘤 (GBM) 进展中的作用仍然鲜为人知。这些发现表明谷氨酰胺分解在调节信号转导和代谢重编程中的新功能,为谷氨酰胺分解在GBM进展中的独特作用提供了进一步的证据。

    REF: Yang R, Zhang G, Meng Z, et al. GDH1-catalytic glutaminolysis feedback activate EGFR/PI3K/AKT pathway and reprogram glioblastoma metabolism. Neuro Oncol. Published online October 24, 2024. doi:10.1093/neuonc/noae222 PMID: 39446525

  • ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells

    ROR1通过稳定GRB2促进胶质瘤干细胞c-fos表达促进胶质母细胞瘤生长

    Glioma stem cells (GSCs) are the root cause of tumorigenesis, recurrence, and therapeutic resistance in glioblastoma (GBM), the most prevalent and lethal type of primary adult brain malignancy. The exploitation of novel methods targeting GSCs is crucial for the treatment of GBM. In this study, we investigate the function of the novel ROR1-GRB2-c-Fos axis in GSCs maintenance and GBM progression. ROR1 plays essential roles in GSCs maintenance through binding to GRB2 and activation of ERK/c-Fos signaling, which highlights the therapeutic potential of targeting the ROR1-GRB2-c-Fos axis.

    胶质瘤干细胞 (GSCs) 是胶质母细胞瘤 (GBM) 的肿瘤发生,复发和治疗抵抗的根本原因,胶质母细胞瘤是原发性成人脑恶性肿瘤中最普遍和致命的类型。开发靶向GSCs的新方法对于治疗GBM至关重要。在这项研究中,我们调查了新的ROR1-GRB2-c-Fos轴在GSCs维持和GBM进展中的功能。ROR1通过结合GRB2和激活ERK/c-fos信号传导在GSCs维持中发挥重要作用,这突出了靶向ROR1-GRB2-c-Fos轴的治疗潜力。

    REF: Zhu H, Cheng L, Liu D, et al. ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells. Neuro Oncol. Published online October 24, 2024. doi:10.1093/neuonc/noae224 PMID: 39447031

  • Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions

    青少年和年轻人的中枢神经系统肿瘤: 神经肿瘤学会关于诊断,管理和未来方向的共识评论

    Adolescents and young adults (AYAs; ages 15–39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor representation in clinical trials. Brain tumors are the second most common tumor type in AYA, with malignant brain tumors being the most common cause of cancer-related death. The 2021 WHO Classification for central nervous system (CNS) Tumors highlights the importance of integrated molecular characterization with histologic diagnosis in several tumors relevant to the AYA population. In this position paper from the Society for Neuro-Oncology (SNO), the diagnosis and management of CNS tumors in AYA is reviewed, focusing on the most common tumor types in this population, namely glioma, medulloblastoma, ependymoma, and CNS germ cell tumor. Current challenges and future directions specific to AYA are also highlighted. Finally, possible solutions to address barriers in the care of AYA patients are discussed, emphasizing the need for multidisciplinary and collaborative approaches that span the pediatric and adult paradigms of care, and incorporating advanced molecular testing, targeted therapy, and AYA-centered care.

    青少年和年轻人 (AYAs; 年龄15-39岁) 是面临肿瘤护理挑战的弱势群体,包括获得专业护理,护理过渡,独特的肿瘤生物学以及在临床试验中的代表性不佳。脑肿瘤是AYA中第二常见的肿瘤类型,恶性脑肿瘤是癌症相关死亡的最常见原因。2021 WHO对中枢神经系统 (CNS) 肿瘤的分类强调了在与AYA人群相关的几种肿瘤中,将分子表征与组织学诊断相结合的重要性。在神经肿瘤学会 (SNO) 的立场文件中,对AYA中CNS肿瘤的诊断和管理进行了综述,重点关注该人群中最常见的肿瘤类型,即神经胶质瘤,髓母细胞瘤,室管膜瘤和CNS生殖细胞肿瘤。还强调了AYA特有的当前挑战和未来方向。最后,讨论了解决AYA患者护理障碍的可能解决方案,强调需要跨儿科和成人护理范式的多学科和协作方法,并结合先进的分子测试,靶向治疗和以AYA为中心的护理。

    REF: Lim-Fat MJ, Bennett J, Ostrom Q, et al. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology consensus review on diagnosis, management, and future directions. Neuro Oncol. Published online October 23, 2024. doi:10.1093/neuonc/noae186 PMID: 39441704

  • Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort

    CNS WHO 3级少突胶质细胞瘤IDH突变体和1p/19q共删除的预后因素的重新评估: 法国POLA队列的经验教训

    In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis). Necrosis and CDKN2A HD are adverse prognostic factors of WHO grade 3 oligodendrogliomas, IDH-mutant, and 1p/19q co-deleted. Besides, in group 1 patients, lack of CE is a factor of better prognosis.

    在POLA队列中,已经描述了3个病理组的CNS WHO 3级少突胶质细胞瘤IDH突变体和1p/19q共缺失: 组1 (仅高有丝分裂计数),组2 (微血管增殖MVP和无坏死),和组3 (MVP和坏死)。坏死和CDKN2A HD是WHO 3级少突胶质细胞瘤,IDH突变体和1p/19q共缺失的不良预后因素。此外,在第1组患者中,缺乏CE是预后较好的因素。

    REF: Figarella-Branger D, Colin C, Mokhtari K, et al. Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: lessons from the French POLA cohort. Neuro Oncol. Published online October 21, 2024. doi:10.1093/neuonc/noae221 PMID: 39432559

  • 1
  • 2
  • 3
前往
更多
查看更多